When: September 15 @ 5:00 pm - 6:00 pm ET
Join Converge Consulting for a webinar on gating investment successfully when preparing for commercial supply chain launch. Experts will discuss:
- The importance of gating strategies for managing risk and uncertainty in commercial supply chain launch preparation
- Approaches to gating in life science companies, linked to company objectives
- Advantages and disadvantages of choosing one strategy versus another
- Best practices for planning and building out your commercial supply chain
- Challenges that may arise as you move through key product development and data milestones
The former Senior Director of US Distribution, Trade & GPO for Oncopeptides will also share his first-hand experience preparing for a U.S. launch with limited resources.
Jeremy Friedler (Moderator)
Practice Director, Supply Chain & Operations, Converge Consulting
Jeremy Friedler is a biotechnology and pharmaceutical consultant with 15+ years of strategy and operations experience in the life sciences industry. Jeremy brings knowledge and expertise in clinical and commercial supply chain management, strategic and long-range operations planning, supplier/CMO management, small and large molecule manufacturing/CMC and cGMP quality. Through his work with emerging and established biopharma companies he has a unique and well-rounded perspective for addressing a range of challenges these companies face. Prior to Converge, Jeremy was a senior manager in the Pharmaceutical & Life Sciences practice at PricewaterhouseCoopers, providing operations advisory services for corporate strategic initiatives for mid-sized to global biopharmaceutical companies, as well as roles with Maxiom Consulting Group, ARIAD Pharmaceuticals, and Alnylam Pharmaceuticals.
Alex Spivak
Senior Consultant, Commercial Launch Planning, Converge Consulting
Alex Spivak has close to 20 years of experience in strategy and process optimization with a focus on business process analysis and operations management. Alex works with emerging biotech and pharmaceutical companies specializing in rare diseases, ultra-rare diseases, and cell/gene therapy. For early-stage companies, he supports the development of strategies and infrastructure for manufacturing, quality, IT systems, and supply chain distribution, as well as participates in conducting strategy and risk assessments along with 3-5-year integrated commercial roadmaps. For late-stage companies, he leads the evaluation of PAI and commercial launch readiness, along with developing commercial launch project plans.
Chris Wixson
Senior Director, Distribution & GPOs, AVEO Oncology
Chris Wixson has spent 25+ years in specialty distribution, trade, GPO and market access experience with a focus on the oncology segment. Prior to his current role with AVEO Oncology, Chris served as the Senior Director of US Distribution, Trade & GPOs for Oncopeptides. This followed two decades at McKesson Specialty, where he led field distribution sales teams, launched the Onmark GPO, and helped lead the US Oncology GPO.